mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-1-95-100mrj-1538Research ArticleОБЗОРЫREVIEWSПроблемы контрацепции при ревматических заболеваниях: современное состояние проблемы и перспективыIssues of contraception in rheumatic diseases: current status of the problem and perspectiveshttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

115522, Москва, Каширское шоссе, 34А;

680000, Хабаровск, ул. Муравьева-Амурского, 35

34A, Kashirskoe Shosse, Moscow 115522;

35, Muraviev-Amurskiy Street, Khabarovsk 680000

https://orcid.org/0000-0002-0627-3902СметникА. А.SmetnikA. A.

117997, Москва, ул. Академика Опарина, 4

4, Akademik Oparin Street, Moscow 117997

https://orcid.org/0000-0002-1771-6246ДубининаТ. В.DubininaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Far-Eastern State Medical University, Ministry of Health of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава РоссииРоссияNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Ministry of Health of the RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation20242002202418195100Copyright © Паневин Т.С., Сметник А.А., Дубинина Т.В., 20242024Паневин Т.С., Сметник А.А., Дубинина Т.В.Panevin T.S., Smetnik A.A., Dubinina T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1538

Контрацепция является важным аспектом поддержания репродуктивного здоровья пациентов с ревматическими заболеваниями. В первую очередь это связано с необходимостью планирования беременности при большинстве иммуновоспалительных ревматических заболеваний (ИВРЗ). С одной стороны, наличие и активность ИВРЗ может влиять на течение беременности, с другой – беременность, сопровождающаяся изменением общего гормонального фона, нередко является фактором изменения активности ИВРЗ. Часть пациенток принимает препараты с потенциальным тератогенным эффектом. Планирование беременности при ИВРЗ может способствовать ее оптимальному исходу, а также минимизации рисков обострения ИВРЗ. Учитывая широкий спектр применяемых в настоящее время барьерных и гормональных контрацептивов, внедрение в клиническую практику новых препаратов, данные о возможности их использования приобретают особую актуальность для ревматологов практического здравоохранения.

Contraception is an important aspect of reproductive health in patients with rheumatic diseases. This is primarily due to the fact that in most immuneinflammatory rheumatic diseases (IRD) pregnancy must be planned. On one hand, the presence and activity of IRD can influence the course of the pregnancy, but on the other hand, pregnancy, which is accompanied by changes in general hormonal levels, is often a factor that alters the activity of IRD. Some patients take medication with potentially teratogenic effects. Planning a pregnancy during IRD can contribute to its optimal progression and minimize the risks of exacerbation of IRD. Given the wide range of barrier and hormonal contraceptives currently in use and the introduction of new drugs into clinical practice, data on the possibility of their use are of particular importance to rheumatologists in practical healthcare.

контрацепциябеременностьревматические заболеванияcontraceptionpregnancyrheumatic diseasesСтатья подготовлена в рамках научной темы №1021051503111-9 «Совершенствование диагностики и фармакотерапии спондилоартритов на основании сравнительных результатов изучения прогностических (в том числе молекулярно-биологических, молекулярно-генетических, клинико-визуализационных) факторов прогрессирования заболевания и уровня качества жизни больных». ИсследReferencesSammaritano LR. Contraception in Patients with Rheumatic Disease. Rheum Dis Clin North Am. 2017 May;43(2):173-188. doi: 10.1016/j.rdc.2016.12.001.Sammaritano LR. Contraception in Patients with Rheumatic Disease. Rheum Dis Clin North Am. 2017 May;43(2):173-188. doi: 10.1016/j.rdc.2016.12.001.Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008 Jun 15;59(6):863-6. doi: 10.1002/art.23712.Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008 Jun 15;59(6):863-6. doi: 10.1002/art.23712.Yazdany J, Trupin L, Kaiser R, et al. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? Arthritis Care Res (Hoboken). 2011 Mar;63(3):358-65. doi: 10.1002/acr.20402. Epub 2010 Nov 15.Yazdany J, Trupin L, Kaiser R, et al. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? Arthritis Care Res (Hoboken). 2011 Mar;63(3):358-65. doi: 10.1002/acr.20402. Epub 2010 Nov 15.Østensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol. 2007 Jun;34(6):1266-9. Epub 2007 May 15.Østensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol. 2007 Jun;34(6):1266-9. Epub 2007 May 15.Ferguson S, Trupin L, Yazdany J, et al. Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication. Lupus. 2016 Jan; 25(1):12-7. doi: 10.1177/0961203315596079. Epub 2015 Jul 19.Ferguson S, Trupin L, Yazdany J, et al. Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication. Lupus. 2016 Jan; 25(1):12-7. doi: 10.1177/0961203315596079. Epub 2015 Jul 19.Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plann Perspect. 1991 Sep-Oct;23(5): 226-7, 232.Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plann Perspect. 1991 Sep-Oct;23(5): 226-7, 232.d'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007 Jun;75(6 Suppl):S2-7. doi: 10.1016/j.contraception.2006.12.024. Epub 2007 Apr 19.d'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007 Jun;75(6 Suppl):S2-7. doi: 10.1016/j.contraception.2006.12.024. Epub 2007 Apr 19.Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002 Feb;65(2):129-32. doi: 10.1016/s0010-7824(01)00302-x.Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002 Feb;65(2):129-32. doi: 10.1016/s0010-7824(01)00302-x.Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007 Aug;197(2):144.e1-8. doi: 10.1016/j.ajog.2007.03.031.Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007 Aug;197(2):144.e1-8. doi: 10.1016/j.ajog.2007.03.031.Кузнецова ИВ. Метаболические эффекты комбинированной гормональной контрацепции и риск тромботических осложнений. Акушерство и гинекология. 2016;(7):108-114.Kuznetsova IV. Metabolic effects of combined hormonal contraception and a risk for thrombotic events. Akusherstvo i ginekologiya. 2016;(7):108-114. (In Russ.).Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ. 2015 Oct 8: 351:h4847. doi: 10.1136/bmj.h4847.Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ. 2015 Oct 8: 351:h4847. doi: 10.1136/bmj.h4847.Morimont L, Haguet H, Dogne JM, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021 Dec 9:12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021.Morimont L, Haguet H, Dogne JM, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021 Dec 9:12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021.Tanis BC, Rosendaal FR. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med. 2003 Feb;3(1):69-84. doi: 10.1055/s-2003-38334.Tanis BC, Rosendaal FR. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med. 2003 Feb;3(1):69-84. doi: 10.1055/s-2003-38334.Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021 Apr;103(4): 213-221. doi: 10.1016/j.contraception.2021.01.001. Epub 2021 Jan 9.Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021 Apr;103(4): 213-221. doi: 10.1016/j.contraception.2021.01.001. Epub 2021 Jan 9.Оразов МР, Радзинский ВЕ, Долгов ЕД, Ермаков ВВ. Эндокринно-метаболические эффекты оральных контрацептивов, содержащих эстетрол и дроспиренон. Вопросы гинекологии, акушерства и перинатологии. 2022;21(4):146-150.Orazov MR, Radzinsky VE, Dolgov ED, Ermakov VV. Endocrine and metabolic effects of oral contraceptives containing estetrol and drospirenone. Voprosy ginekologii, akusherstva i perinatologii. 2022;21(4):146-150. (In Russ.).Оразов МР, Радзинский ВЕ, Долгов ЕД, Ермаков ВВ. Риски венозных тромбоэмболий при использовании гормональных контрацептивов, содержащих эстетрол и дроспиренон. Вопросы гинекологии, акушерства и перинатологии. 2022;21(6): 125-130.Orazov MR, Radzinsky VE, Dolgov ED, Ermakov VV. Risks of venous thromboembolism when using hormonal contraceptives containing estetrol and drospirenone. Voprosy ginekologii, akusherstva i perinatologii. 2022; 21(6):125-130. (In Russ.).American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008 Sep;112(3): 727-30. doi: 10.1097/AOG.0b013e318188d1ec.American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008 Sep;112(3): 727-30. doi: 10.1097/AOG.0b013e318188d1ec.Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception. 2001 Aug;64(2):125-33. doi: 10.1016/s0010-7824(01)00234-7.Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception. 2001 Aug;64(2):125-33. doi: 10.1016/s0010-7824(01)00234-7.Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8. doi: 10.1056/NEJMoa051135.Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8. doi: 10.1056/NEJMoa051135.Sanchez-Guerrero J, Uribe AG, JimenezSantana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24): 2539-49. doi: 10.1056/NEJMoa050817.Sanchez-Guerrero J, Uribe AG, JimenezSantana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24): 2539-49. doi: 10.1056/NEJMoa050817.Chabbert-Buffet N, Amoura Z, Scarabin PY, et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception. 2011 Mar;83(3):229-37. doi: 10.1016/j.contraception.2010.08.012. Epub 2010 Oct 30.Chabbert-Buffet N, Amoura Z, Scarabin PY, et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception. 2011 Mar;83(3):229-37. doi: 10.1016/j.contraception.2010.08.012. Epub 2010 Oct 30.Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis. 1996 Feb;55(2):94-8. doi: 10.1136/ard.55.2.94.Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis. 1996 Feb;55(2):94-8. doi: 10.1136/ard.55.2.94.Drossaers-Bakker KW, Zwinderman AH, van Zeben D, et al. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002 May;61(5):405-8. doi: 10.1136/ard.61.5.405.Drossaers-Bakker KW, Zwinderman AH, van Zeben D, et al. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002 May;61(5):405-8. doi: 10.1136/ard.61.5.405.Насонов ЕЛ, Решетняк ТМ, Алекберова ЗС. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5):4-14.Nasonov EL, Reshetniak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: a link between thrombosis autoimmunity. Terapevticheskii arkhiv. 2020;92(5):4-14. (In Russ.).Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009 Jun;36(6):1195-9. doi: 10.3899/jrheum.081194. Epub 2009 May 15.Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009 Jun;36(6):1195-9. doi: 10.3899/jrheum.081194. Epub 2009 May 15.Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009 Feb;68(2):238-41. doi: 10.1136/ard.2008.093013. Epub 2008 Sep 9.Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009 Feb;68(2):238-41. doi: 10.1136/ard.2008.093013. Epub 2008 Sep 9.Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ. 2015 Oct 8: 351:h4847. doi: 10.1136/bmj.h4847.Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ. 2015 Oct 8: 351:h4847. doi: 10.1136/bmj.h4847.Yamakami LY, de Araujo DB, Silva CA, et al. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20(5):523-526. doi: 10.1177/0961203310383300Yamakami LY, de Araujo DB, Silva CA, et al. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20(5):523-526. doi: 10.1177/0961203310383300Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012 Aug; 24(4):235-40. doi: 10.1097/GCO.0b013e328355871d.Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012 Aug; 24(4):235-40. doi: 10.1097/GCO.0b013e328355871d.Le Moigne E, Tromeur C, Delluc A, et al. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study. Haematologica. 2016 Jan;101(1):e12-4. doi: 10.3324/haematol.2015.134882. Epub 2015 Oct 9.Le Moigne E, Tromeur C, Delluc A, et al. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study. Haematologica. 2016 Jan;101(1):e12-4. doi: 10.3324/haematol.2015.134882. Epub 2015 Oct 9.ACOG Committee on Practice BulletinsGynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006 Jun;107(6):1453-72. doi: 10.1097/00006250-200606000-00055.ACOG Committee on Practice BulletinsGynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006 Jun;107(6):1453-72. doi: 10.1097/00006250-200606000-00055.Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006;15(12): 877-80. doi: 10.1177/0961203306071706.Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006;15(12): 877-80. doi: 10.1177/0961203306071706.Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar;76(3):476- 485. doi: 10.1136/annrheumdis-2016-209770. Epub 2016 Jul 25.Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar;76(3):476- 485. doi: 10.1136/annrheumdis-2016-209770. Epub 2016 Jul 25.Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art. 41191. Epub 2020 Feb 23.Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art. 41191. Epub 2020 Feb 23.

The authors declare that there are no conflicts of interest present.